Standardized SEC financial data for PUMA BIOTECHNOLOGY, INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001401667 · NASDAQ · Pharmaceutical Preparations.
Ratios for fiscal year 2025, standardized from SEC filings.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $225.1M | $253.2M | $228.0M | $235.6M | $230.5M | $228.4M |
| Cost of revenue | $39.4M | $63.7M | $55.1M | $62.7M | $64.4M | $58.2M |
| Gross profit | $185.7M | $189.5M | $172.9M | $173.0M |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $85.3M | $69.8M | $76.2M | $84.6M | $86.8M | $91.6M |
| Inventory | $3.5M | $7.1M | $4.5M | $7.1M | $8.7M | $5.5M |
| Total current assets | $146.1M | $140.0M | $134.3M | $156.2M |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $773K | $20.6M | -$15.8M | $27.0M | $38.9M | $41.8M |
| Capital expenditures | $46K | $0 | $0 | $140K | $56K | $71K |
| Free cash flow | $727K | $20.6M | -$15.8M | $26.9M |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/PBYI/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/PBYI/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $166.1M |
| $170.2M |
| R&D expense | $97.7M | $71.9M | $52.2M | $50.4M | $54.9M | $62.1M |
| SG&A expense | $118.5M | $116.3M | $90.0M | $89.9M | $80.2M | $70.8M |
| Operating income | -$30.4M | $1.3M | $23.7M | $32.6M | $31.0M | $37.3M |
| EBITDA | -$20.4M | $12.6M | $33.6M | $44.2M | $42.5M | $48.2M |
| Interest expense | $14.0M | $12.8M | $11.6M | $13.3M | $10.8M | $5.8M |
| Pretax income | -$59.8M | -$28.8M | $457K | $22.7M | $24.1M | $35.8M |
| Income tax | $207K | $324K | $455K | $1.1M | $6.2M | $4.7M |
| Net income | -$60.0M | -$29.1M | $2K | $21.6M | $30.3M | $31.1M |
| EPS (diluted) | $-1.52 | $-0.72 | $0.00 | $0.45 | $0.62 | $0.61 |
Standardized from PUMA BIOTECHNOLOGY, INC.'s SEC filings — per-share figures split-adjusted. Full history via the API.
| $147.7M |
| $162.7M |
| Property, plant & equipment | $2.5M | $1.8M | $1.1M | $855K | $515K | $187K |
| Total assets | $244.2M | $226.6M | $222.1M | $230.5M | $213.3M | $216.3M |
| Total current liabilities | $114.3M | $109.6M | $77.5M | $99.4M | $96.1M | $81.3M |
| Long-term debt | $84.0M | $102.0M | $102.0M | $102.0M | $68.0M | $22.7M |
| Total debt | $98.3M | $102.0M | $102.0M | $136.0M | $113.3M | $45.2M |
| Total liabilities | $250.2M | $229.0M | $200.5M | $177.1M | $121.2M | $86.0M |
| Retained earnings | -$1.34B | -$1.37B | -$1.37B | -$1.35B | -$1.31B | -$1.28B |
| Total equity | -$6.0M | -$2.4M | $21.6M | $53.4M | $92.1M | $130.3M |
| $38.9M |
| $41.7M |
| Investing cash flow | $33.4M | -$10.9M | $7.1M | -$19.1M | -$20.4M | -$36.2M |
| Financing cash flow | -$9.9M | -$31.9M | $12.2M | $0 | -$33.8M | -$45.2M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 |